Kingdon Capital Management, L.L.C. Aldeyra Therapeutics, Inc. Transaction History
Kingdon Capital Management, L.L.C.
- $673 Million
- Q3 2025
A detailed history of Kingdon Capital Management, L.L.C. transactions in Aldeyra Therapeutics, Inc. stock. As of the latest transaction made, Kingdon Capital Management, L.L.C. holds 1,331,791 shares of ALDX stock, worth $6.75 Million. This represents 1.02% of its overall portfolio holdings.
Number of Shares
1,331,791
Previous 1,331,791
-0.0%
Holding current value
$6.75 Million
Previous $5.1 Million
35.0%
% of portfolio
1.02%
Previous 0.8%
Shares
2 transactions
Others Institutions Holding ALDX
# of Institutions
143Shares Held
40MCall Options Held
344KPut Options Held
71.7K-
Knoll Capital Management, LLC Miami, FL5.48MShares$27.8 Million15.99% of portfolio
-
Perceptive Advisors LLC New York, NY5.22MShares$26.5 Million0.06% of portfolio
-
Black Rock Inc. New York, NY3.62MShares$18.4 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.59MShares$18.2 Million0.0% of portfolio
-
Ardsley Advisory Partners LP Stamford, CT1.9MShares$9.63 Million1.4% of portfolio
About Aldeyra Therapeutics, Inc.
- Ticker ALDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,323,100
- Market Cap $296M
- Description
- Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...